ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015. It was four-to sixfold more active than other fluoroquinolones, including against levofloxacin-resistant strains of S. pneumoniae, methicillin-resistant Staphylococcus aureus, and Prevotella species.
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Bacterial sinusitis affects approximately 30 million Americans yearly (14, 18) . While acute sinusitis primarily involves aerobes, anaerobes are frequently isolated from patients with chronic sinusitis (1, 3, 7, 10) . Quinolones have been used to treat acute sinusitis with targeted activity against pneumococci, Haemophilus spp., and Moraxella catarrhalis; however, resistance has emerged to beta-lactams (6, 15) and fluoroquinolones (2, 4, 5, 17) .
In 2000 in Hong Kong 50% of Streptococcus pneumoniae isolates were highly penicillin resistant and 27% of these were fluoroquinolone resistant (8) due to a fluoroquinolone-resistant variant of the Spanish 23F-1 clone that been associated with penicillin-resistant S. pneumoniae in Canada (6) . While rates of penicillin-nonsusceptible S. pneumoniae vary by geographic region (15) , approximately 22% of these isolates are also multidrug resistant (2) . The rate of fluoroquinolone resistance in S. pneumoniae in the United States remains low at Ͻ1.5% of isolates (2) . It has been suggested that use of "less potent derivatives" of fluoroquinolones may initiate resistance, creating a need for the development of more potent fluoroquinolones.
ABT-492 (WQ-3034) is a new fluoroquinolone with a 6-amino-3,5-difluoropyridin-2-yl group at the N-1 position and a chlorine at the C-8 position. The drug has a broad spectrum of activity, including against quinolone-resistant pathogens ( Strains were isolated from antral puncture specimens obtained from adult patients with sinusitis between 1994 and 2001 and were identified by standard criteria (9, 11) . The numbers and species of clinical isolates tested are given in Table 1 .
Suppliers of standard laboratory powders were as indicated: ABT-492, Abbott Laboratories, Abbott Park, Ill.; amoxicillin-clavulanate and cefuroxime, Glaxo SmithKline, Philadelphia, Pa.; moxifloxacin, Bayer Corp., West Haven, Conn.; levofloxacin, R. W. Johnson Pharmaceutical Research Institute, Raritan, N.J.; The results are presented in Table 1 . ABT-492 performed well in our study with 325 of 326 (99.7%) sinus isolates, both aerobic and anaerobic, susceptible to Յ4 g of drug/ml. For only one isolate of Pseudomonas aeruginosa, which was resistant to all the quinolones tested, did ABT-492 have a MIC of 16 g/ml. For three other isolates, two strains of Achromobacter xylosoxidans and one strain of Bacteroides uniformis, the MICs of ABT-492 were 4 g/ml. For an additional five strains (one strain each of Acinetobacter baumannii, Bilophila wadsworthia, and Veillonella species and two strains of P. aeruginosa) the MICs of ABT-492 were 2 g/ml.
ABT-492 was active against all pneumococci at Յ0.06 g/ml and was five-to sevenfold more active than levofloxacin, moxifloxacin, and gatifloxacin on a weight basis. Twenty percent of our pneumococcal sinus isolates were nonsusceptible to penicillin, and 10% were resistant to clindamycin. ABT-492 exhibited excellent activity against one isolate that was resistant to the other fluoroquinolones. This is in accord with the work of Nilius et al. (42nd ICAAC), who studied 30 quinolone-resistant S. pneumoniae isolates and found ABT-492 to have a MIC at which 90% of isolates tested were inhibited (MIC 90 ) of 0.12 g/ml compared to a levofloxacin MIC 90 of 16 g/ml. Smith et al. (42nd ICAAC) studied 75 Canadian strains of ciprofloxacin-resistant S. pneumoniae and reported a MIC 90 of ABT-492 of 0.25 g/ml compared to MIC 90 s of gatifloxacin, levofloxacin, and moxifloxacin of 8, 16, and 4 g/ml, respectively. Zhanel et al. (42nd ICAAC) reported the comparative activities of ABT-492 against 850 strains of S. pneumoniae isolated from Canadian patients with lower respiratory tract infections in 2002 and found ABT-492 to be "the most powerful agent tested against respiratory isolates of S. pneumoniae," including penicillinresistant, macrolide-resistant, doxycycline-resistant, and quinolone-resistant strains.
In our study, 45% of H. influenzae and other Haemophilus species isolates were beta-lactamase producers and all were susceptible to all the fluoroquinolones tested, with ABT-492 being 4-to 10-fold more active. Against Haemophilus species 1 g/ml) , 11 isolates of Prevotella species (MIC 90 , 1 g/ml), 12 isolates of Clostridium perfringens (MIC 90 , 0.008 g/ml), and 10 isolates of C. difficile (MIC 90 , 2 g/ml). In our study, ABT-492 performed well against the anaerobes tested, with one isolate of B. uniformis requiring 4 g of ABT-492/ml for inhibition and all other isolates being inhibited by Յ2 g/ml.
Amoxicillin-clavulanate performed well against all the anaerobes and many of the aerobes studied with the exception of the Enterobacteriaceae and nonfermenting gram-negative bacilli as previously reported (5) . Levofloxacin showed good activity against most aerobic and many anaerobic sinus isolates with the exception of 8% of anaerobes (especially Prevotella melaninogenica). Moxifloxacin and gatifloxacin had similar activities against both aerobes and anaerobes.
ABT-492 was the most active agent tested with an improved and broader spectrum of activity compared with those of currently available quinolones. It merits further evaluation as a therapeutic alternative in both acute and chronic sinusitis.
